Rawmax Pharmaceutical Private Limited - Due diligence report

A 360° intelligence report on Rawmax Pharmaceutical Private Limited: trust score, financial health, credit view, compliance, directors, grow…

2015-05-19 Nagpur, Maharashtra Strike Off Unlisted Active Non-Compliant
Share
RP Rawmax Pharmaceutical Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Rawmax Pharmaceutical Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
38/100
Trust Score
Caution Indicated

Rawmax Pharmaceutical Private Limited is assessed as Caution Indicated with a Trust Score of 38/100. Rawmax Pharmaceutical Private Limited is a private limited indian non-government company incorporated in 2015, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a high compliance risk and high financial risk profile.

Report generated on 18 Jul 2026 from the latest processed filings. Rawmax Pharmaceutical Private Limited snapshot & full profile →

Financial Health › Weak
Overall Assessment CautionWeakNeutralGoodStrong Weak
Compliance › Caution

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreCaution Indicated
38/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
10/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
30/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
50/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreModerate
55/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
70/100
Revenue, profit, asset and hiring momentum.
Distress ScoreCaution Indicated
35/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 2 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 50/100 Moderate
  • Negative operating earnings - debt service depends on external support.
  • No open charges - unencumbered balance sheet.
  • Working-capital cover adequate.

Charges position: 0 open (-) · 0 satisfied (-).

Compliance Score: 10/100 Caution Indicated
  • Company status is "Strike Off" - not Active.
  • Marked ACTIVE non-compliant (INC-22A).
  • Last balance sheet is for Mar 2017 - filings overdue.
05

Director Intelligence

Stability score: 55/100
NameDIN / PANDesignationAppointedTenureDIN status
UMESH KISANRAO WADEKAR 01234567 Director 01/04/2018 6 yrs Approved
SANJAY BECHAN CHOURASIA 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • SANJAY BECHAN CHOURASIA has DIN status "Deactivated due to non-filing of DIR-3 KYC".
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
06

Ownership & Group Intelligence

As per FY 2017 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 70 · Distress 35
Growth signals & trust indicators
Steady revenue growth: +38% over 1 year(s).
Latest year revenue grew 1.42.
Operating for 11+ years.
Distress signals & risk flags
Negative net worth.
Statutory filings appear overdue.
Adverse company status: Strike Off.
Compliance score is weak (10/100).
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence26/100
Caution indicated
Suitability as a supplier / customer counterparty.
  • Check the compliance flags before onboarding.
  • 3 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment34/100
Enhanced diligence advised
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance gaps should be priced into terms.
Investor view48/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • 2 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management churn warrants questions.
09

MCA Filings & Events Timeline

Latest 8 events
01 Feb 2022
Director ceased
KAMALKUMAR NITYANAND RAWAT
30 Sep 2017
Last AGM held
Annual general meeting
31 Mar 2017
Latest balance sheet
Filed with ROC
07 Oct 2015
Director appointed
SANJAY BECHAN CHOURASIA (Director)
Director ceased
AMIT DIWARE
22 Jun 2015
Director ceased
SHRIRAM MANIKARAO MASLEKAR
19 May 2015
Incorporated
Registered with Roc Mumbai
Director appointed
UMESH KISANRAO WADEKAR (Director)
10

Key Observations

Auto-generated from the data above
Revenue grew 2.1x over the last 1 financial year(s).
Net profit margin moved from 24% to 0.86.
2 active director(s) / partner(s); review board churn before relying on management continuity.
Promoters hold a dominant controlling stake as per the FY 2017 annual return.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Manraj Tradecom Private Limited U52100WB2007PTC117393 Kolkata, West Bengal, India
In-Mac India Pvt Ltd U51909GJ1994PTC023196 Ahmedabad, Gujarat, India
Sixteen Celestial Learnings Private Limited U80302RJ2014PTC046269 Didwana, Rajasthan, India
Mugdha Expo Private Limited U18204DL2010PTC197563 New Delhi, Delhi, India
Mfpl Exports Private Limited U24294TN1994PTC027607 Tamilnadu, Tamil Nadu, India
Panchparv Distributors Private Limited U51909WB2012PTC179998 Kolkata, West Bengal, India
Chidambaram Poly Bags & Chemicals Private Limited U24299TN2013PTC092513 Chennai, Tamil Nadu, India
Nischal Vyapaar Private Limited U51909WB2001PTC092913 Kolkata, West Bengal, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Rawmax Pharmaceutical Private Limited before audits and certifications: compliance score 10/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Rawmax Pharmaceutical Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Enhanced diligence advised. Credit risk score 50/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 70/100, margin trends, ownership structure and peer set for Rawmax Pharmaceutical Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Caution indicated. Trust score 38/100, distress signals and MSME payment-delay disclosures - know whether Rawmax Pharmaceutical Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Rawmax Pharmaceutical Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Rawmax Pharmaceutical Private Limited an active company?

Rawmax Pharmaceutical Private Limited has MCA status “Strike Off” with a compliance score of 10/100 (Caution Indicated).

Is Rawmax Pharmaceutical Private Limited financially healthy?

Rawmax Pharmaceutical Private Limited has a Financial Health Score of 30/100 (Caution Indicated) based on its filed financial statements.

Should I do business with Rawmax Pharmaceutical Private Limited?

Its overall Trust Score is 38/100 (Caution Indicated). Vendor verdict: Caution indicated. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Rawmax Pharmaceutical Private Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 2 active director(s) are on record.

Does Rawmax Pharmaceutical Private Limited have loans or charges against its assets?

No charges are registered against this company - an unencumbered balance sheet.

Is Rawmax Pharmaceutical Private Limited up to date with its ROC filings?

Marked ACTIVE non-compliant (INC-22A). Overall compliance score: 10/100 (Caution Indicated).

Is it risky to lend to Rawmax Pharmaceutical Private Limited?

Its Credit Risk Score is 50/100 (Moderate). Banker verdict: Enhanced diligence advised.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.